In lung cancer, smokers have 10 times more genetic damage than never-smokers

September 13, 2012, Washington University School of Medicine

Lung cancer patients with a history of smoking have 10 times more genetic mutations in their tumors than those with the disease who have never smoked, according to a new study from Washington University School of Medicine in St. Louis.

"None of us were surprised that the genomes of smokers had more than the genomes of never-smokers with lung cancer," says senior author Richard K. Wilson, PhD, director of The Genome Institute at Washington University. "But it was surprising to see 10-fold more mutations. It does reinforce the old message – don't smoke."

The study appears online Sept. 13 in Cell.

Lung cancer patients with a history of smoking have 10 times more genetic mutations in their tumors than those with the disease who have never smoked, according to a new study from Washington University School of Medicine in St. Louis. Credit: Jim Dryden

Overall, the analysis identified about 3,700 mutations across all 17 with non-small cell lung cancer, the most common type. Twelve patients had a history of smoking and five did not. In each patient who never smoked, the researchers found at least one mutated gene that can be targeted with drugs currently on the market for other diseases or available through clinical trials. Across all patients, they identified 54 mutated genes already associated with existing drugs.

"Whether these drugs will actually work in patients with these still needs to be studied," says first author Ramaswamy Govindan, MD, an who treats patients at Siteman at Barnes-Jewish Hospital and Washington University. "But papers like this open up the landscape to understand what's happening. Now we need to drill deeper and do studies to understand how these mutations cause and promote cancer, and how they can be targeted for therapy."

Lung cancer is divided into two types – small cell and non-small cell, the latter accounting for about 85 percent of all cases. Within non-small cell lung cancer are three further classifications. This current analysis included two of them. Sixteen patients had and one had large-cell carcinoma.

Govindan and Wilson also were involved in a larger of 178 patients with the third type, squamous cell carcinoma, recently reported in Nature. That study was part of The Cancer Genome Atlas project, a national effort to describe the genetics of common cancers.

"Over the next year or so, we will have studied nearly 1,000 genomes of patients with lung cancer, as part of The Cancer Genome Atlas," says Govindan, who serves as a national co-chair of the lung cancer group. "So we are moving in the right direction – toward future clinical trials that will focus on the specific molecular biology of the patient's cancer."

Indeed, based on the emerging body of genetic research demonstrating common mutations across disparate cancer types, Wilson speculates that the field may reach a point where doctors can label and treat a tumor based on the genes that are mutated rather than the affected organ. Instead of "lung cancer," for example, they might call it "EGFR cancer," after the mutated gene driving tumor growth. Mutations in EGFR have been found in multiple cancers, including lung, colon and breast.

This labeling is relevant, Wilson says, because today targeted therapies are approved based on the diseased organ or tissue. Herceptin®, for example, is essentially a breast cancer drug. But he has seen with mutations in the same gene that Herceptin targets.

"For example, if sequencing revealed that a lung cancer patient has a mutation known to be sensitive to a drug that works in breast tumors with the same genetic alteration, you may want to use that agent in those patients, ideally as part of a clinical trial," he says. "In the coming years, we hope to be treating cancer based more on the altered genetic make-up of the tumor than by the tissue of origin."

Explore further: Two studies could lead to new personalized therapies for lung cancer patients

More information: Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. Sept. 13, 2012.

Related Stories

Two studies could lead to new personalized therapies for lung cancer patients

September 13, 2012
Lung cancer is a leading cause of death worldwide and is associated with very low survival rates. Two new genome-sequencing studies have uncovered novel genes involved in the deadly disease, as well as striking differences ...

Testing for mutations identified in squamous cell lung cancer tumors helps personalize treatment

May 17, 2012
Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations ...

Lung tumors in never-smokers show greater genomic instability than those in smokers

July 5, 2011
Lung adenocarcinomas in people who have never smoked show greater genome instability than those in smokers, supporting the theory that lung cancer in never smokers arises through different pathways, according to research ...

Researchers map potential genetic origins, pathways of lung cancer in nonsmokers

January 9, 2012
Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers -- a first step in developing potential therapeutic ...

The link between TB and a gene mutation that causes lung cancer

January 18, 2012
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease ...

Recommended for you

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

Bladder cancer model could pave the way for better drug efficacy studies

May 21, 2018
Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients ...

Breath test breakthrough for early diagnosis of oesophageal and gastric cancer

May 18, 2018
A breath test can successfully detect oesophageal and gastric cancer and could be used as a first-line test for patients, say researchers.

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas

May 18, 2018
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report ...

Particle shows promise to prevent the spread of triple-negative breast cancer

May 18, 2018
USC researchers have pinpointed a remedy to prevent the spread of triple-negative breast cancer. Metastatic breast cancer is a leading cause of death for women. The findings appear today in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.